



Special Issue

Tackling Cisplatin Resistance in Ovarian Cancer

Guest Editor(s):

Dr. Paola Perego,

Fondazione IRCCS Istituto Nazionale dei
Tumori, Milan, Italy.

Email:

paola.perego@istitutotumori.mi.it

Website:

<https://moh->

[it.pure.elsevier.com/en/persons/paola-perego](https://moh-it.pure.elsevier.com/en/persons/paola-perego)

Submission Deadline:

30 October 2020

Special Issue Introduction

Ovarian cancer is the main cause of cancer-related deaths from gynecological cancer. Because diagnosis occurs primarily as advanced disease, the prognosis is poor. In spite of good response to platinum-based therapy, the development of drug resistance represents a major limitation to cure.

Therefore, efforts are needed to define novel strategies to optimize treatment. Research with preclinical models has provided useful results exploited in an attempt to overcome drug resistance. The evidence that the tumor microenvironment can affect response to treatment has stimulated the investigation of mechanisms underlying the role of cell extrinsic factors in drug-resistance regulation. Besides, the molecular characterization of tumors has favored the definition of the molecular features associated with response to treatment and new insights are expected by the investigation on non-coding RNAs. The search for novel biomarkers accurately predicting clinical outcome for patients with advanced epithelial ovarian cancer appears to be a promising field of investigation.

Benefits

Open Access: The full-text of each published article can be accessed and downloaded from the journal website without any fee. The copyright is owned by all authors.

Free of Charge: We provide free services to authors for manuscripts' processing, publication, and reproduction of photographs.

Rigorous Peer Review: We strictly follow international guidelines (COPE Ethical Guidelines for Peer Reviewers) and ensure rigorous peer review process.

Wide Promotion: The full text of each published article is promoted and widely disseminated across the internet, conferences and academic social media.

